Back to Feed
Stem cell research & therapy|Peer-Reviewed
Preclinical efficacy and safety evaluation of human embryonic stem cell-derived functional hepatocytes for a clinical trial in acute liver failure.
Yi Sun, Juan Yu, Yang Shi, Yang Wang, Xingxiang Duan, Menghan Xie, Qi Ouyang, Yan Zhao, Mei Wang, Baicun Zhou, Caiyun Xu, Guangxiu Lu, Ge Lin
Abstract
Acute liver failure (ALF) is a life-threatening syndrome characterized by rapid deterioration of liver function, resulting in high mortality and posing a substantial global health burden. Human embryonic stem cells (hESCs) possess unlimited self-renewal capacity and pluripotent differentiation potential. Transplantation of hESC-derived hepatocyte-like cells (HPLCs) represents a promising therapeutic strategy for ALF.
Keywords
<Keyword MajorTopicYN="N">Cell therapyDirected differentiationHepatocytesHuman embryonic stem cellsLiver failurePreclinical assessment